close
close

Morbus Osler: Pomalidomide schützt vor Epistaxis

Posted on by Vaseline
Morbus Osler: Pomalidomide schützt vor Epistaxis

Medicines

Tuesday, September 24, 2024

Cleveland – The Thalidomide derivative Pomalidomid, used for 10 years in the treatment of multiple myelomas, is a randomized study of the disease in patients with hereditary telangiectasia (Morbus Osler), which appeared in the New England Journal of Medicine (2024) ; DOI: 10.1056/NEJMoa2312749) publishes results. The autosomal dominant Morbus Osler-Weber-Rendu is associated with a…

Related Posts